166
Views
0
CrossRef citations to date
0
Altmetric
Cardiology

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention

ORCID Icon, , &
Pages 3977-3984 | Received 15 Jul 2023, Accepted 29 Aug 2023, Published online: 31 Aug 2023

References

  • Collaborators GBDCo D. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi:10.1016/S0140-6736(17)32152-9
  • Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386(9994):702–713. doi:10.1016/S0140-6736(15)61220-X
  • Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15(2):173–184. doi:10.11909/j.issn.1671-5411.2018.02.007
  • Moussa ID, Mohananey D, Saucedo J, et al. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. J Am Coll Cardiol. 2020;76(13):1521–1531. doi:10.1016/j.jacc.2020.08.002
  • Oguz M, Akbulut T, Saylik F, Sipal A, Erdal E. Association of coronary artery severity and late in-stent restenosis: an Angiographic Imaging Study. Angiology. 2023. doi:10.1177/00033197221150953
  • Zheng Y, Qi Y, Seery S, et al. Long-term outcomes for Chinese COPD patients after PCI: a Propensity Score Matched, Double-Cohort Study. Front Cardiovasc Med. 2022;9:827635. doi:10.3389/fcvm.2022.827635
  • Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019;198:160–188. doi:10.1016/j.pharmthera.2019.02.013
  • Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart. 2012;98(14):1055–1062. doi:10.1136/heartjnl-2012-301759
  • Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Article. Lancet. 2009;373(9670):1190–1197. doi:10.1016/S0140-6736(09)60552-3
  • Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. Article. BMJ. 2008;337. doi:10.1136/bmj.a1331
  • Stefanini GG, Holmes DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254–265. doi:10.1056/NEJMra1210816
  • Singh AD, Singal AK, Mian A, et al. Recurrent drug-eluting stent in-stent restenosis: a State-of-the-Art review of pathophysiology, diagnosis, and management. Journal Article: Review. Cardiovasc Revasc Med. 2020;21(9):1157–1163. doi:10.1016/j.carrev.2020.01.005
  • Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011;140(3):604–610. doi:10.1378/chest.10-2644
  • Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. doi:10.1016/j.jacc.2018.08.1038
  • Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
  • Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962. doi:10.1136/thx.2009.128082
  • Fu JJ, McDonald VM, Gibson PG, Simpson JL. Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res. 2014;6(4):316–324. doi:10.4168/aair.2014.6.4.316
  • Magnussen H, Watz H. Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbidities. Journal Article. Review. Proc Am Thorac Soc. 2009;6(8):648–651. doi:10.1513/pats.200906-053DP
  • Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. doi:10.1371/journal.pone.0037483
  • Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768. doi:10.1136/thx.2010.155333
  • McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J. 2012;39(5):1097–1103. doi:10.1183/09031936.00124811
  • Pelgrim CE, Peterson JD, Gosker HR, et al. Psychological co-morbidities in COPD: targeting systemic inflammation, a benefit for both? Eur J Pharmacol. 2019;842:99–110. doi:10.1016/j.ejphar.2018.10.001
  • Hogg JC, Pare PD, Hackett T-L. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Review. Physiol Rev. 2017;97(2):529–552. doi:10.1152/physrev.00025.2015
  • Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
  • Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Journal Article Research Support, Non-U.S. Gov’t. Review. Eur Respir J. 2006;27(3):627–643. doi:10.1183/09031936.06.00024605
  • Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11. doi:10.1513/pats.200404-032MS
  • Wu IH, Sun ZJ, Lu FH, et al. Restrictive spirometry pattern is associated with increased arterial stiffness in men and women. Chest. 2017;152(2):394–401. doi:10.1016/j.chest.2017.03.039
  • Hayıroğlu Mİ, Keskin M, Uzun AO, et al. Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study. Int J Cardiovasc Imaging. 2017;34(3):329–336. doi:10.1007/s10554-017-1241-9
  • Undas A, Jankowski M, Kaczmarek P, Sladek K, Brummel-Ziedins K. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb Res. 2011;128(4):e24–e28. doi:10.1016/j.thromres.2011.05.004
  • Wu BJ, Li Y, Ong KL, et al. Reduction of In-stent restenosis by cholesteryl ester transfer protein inhibition. Arterioscler Thromb Vasc Biol. 2017;37(12):2333-+. doi:10.1161/ATVBAHA.117.310051
  • Van den Berg JC. Management of in-stent restenosis in the superficial femoral artery. J Cardiovasc Surg. 2016;57(2):248–256.
  • Almagro P, Lapuente A, Pareja J, et al. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis. 2015;10:1353–1361. doi:10.2147/COPD.S84482
  • Çinar T, Hayiroğlu Mİ, Şeker M, et al. The predictive value of age, creatinine, ejection fraction score for in-hospital mortality in patients with cardiogenic shock. Coron Artery Dis. 2019;30(8):569–574. doi:10.1097/mca.0000000000000776
  • Hayıroğlu Mİ, Keskin M, Uzun AO, et al. Predictors of In-hospital mortality in patients with ST-Segment elevation myocardial infarction complicated with cardiogenic shock. Heart Lung Circ. 2019;28(2):237–244. doi:10.1016/j.hlc.2017.10.023
  • Çınar T, Şaylık F, Akbulut T, et al. Evaluation of Intermountain risk score for short- and long-term mortality in ST elevation myocardial infarction patients. Angiology. 2022;74(4):357–364. doi:10.1177/00033197221105753
  • Mert Ilker H, Faysal S, Ahmet Çağdaş Y, Murat S, Tufan Ç. Prognostic value of Intermountain Risk Score for short- and long-term mortality in patients with cardiogenic shock. Coron Artery Dis. 2023. doi:10.1097/mca.0000000000001219